Meeting
2015 ASCO Annual Meeting
A phase 3, open-label, randomized, parallel, 2-arm international study of the oral PARP inhibitor talazoparib (BMN 673) in BRCA mutation subjects with locally advanced and/or metastatic breast cancer (EMBRACA).
Authors
Jennifer Keating Litton
The University of Texas MD Anderson Cancer Center, Houston, TX
Jennifer Keating Litton , Joanne Lorraine Blum , Young-Hyuck Im , Miguel Martin , Lida A. Mina , Henri Hubert Roche , Hope S. Rugo , Fran Visco , Charlie Zhang , Nathalie Andrienne Lokker , Debra L. Lounsbury , Wolfgang Eiermann
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Breast Cancer—Triple-Negative/Cytotoxics/Local Therapy
Track
Breast Cancer
Sub Track
Triple-Negative Breast Cancer
Clinical Trial Registration Number
NCT01945775
Citation
J Clin Oncol 33, 2015 (suppl; abstr TPS1107)
DOI
10.1200/jco.2015.33.15_suppl.tps1107
Abstract #
TPS1107
Poster Bd #
217b
Abstract Disclosures
Similar Posters
Poster
2018 ASCO Annual Meeting
EMBRACA: Efficacy outcomes in clinically relevant subgroups comparing talazoparib (TALA), an oral poly ADP ribose polymerase (PARP) inhibitor, to physician's choice of therapy (PCT) in patients with advanced breast cancer and a germline BRCA mutation.
First Author: Hope S. Rugo
Poster
2015 ASCO Annual Meeting
A phase 2 study (2-stage, 2-cohort) of the oral PARP inhibitor talazoparib (BMN 673) in patients with germline BRCA mutation and locally advanced and/or metastatic breast cancer (ABRAZO).
First Author: Nicholas C. Turner
Poster
2014 ASCO Annual Meeting
A phase III randomized trial of niraparib versus physician’s choice in previously treated, HER2-negative, germline-BRCA mutated breast cancer patients: Intergroup study EORTC-1307-BCG and BIG5-13.
First Author: Konstantinos Tryfonidis